• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

理解肥胖与严重 COVID-19 结局之间的关联:系统性炎症反应的因果中介作用。

Understanding the Link Between Obesity and Severe COVID-19 Outcomes: Causal Mediation by Systemic Inflammatory Response.

机构信息

Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA.

Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

出版信息

J Clin Endocrinol Metab. 2022 Jan 18;107(2):e698-e707. doi: 10.1210/clinem/dgab629.

DOI:10.1210/clinem/dgab629
PMID:34473294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8499919/
Abstract

BACKGROUND

Obesity is an established risk factor for severe COVID-19 outcomes. The mechanistic underpinnings of this association are not well-understood.

OBJECTIVE

To evaluate the mediating role of systemic inflammation in obesity-associated COVID-19 outcomes.

METHODS

This hospital-based, observational study included 3828 SARS-CoV-2-infected patients who were hospitalized February to May 2020 at Massachusetts General Hospital (MGH) or Columbia University Irving Medical Center/New York Presbyterian Hospital (CUIMC/NYP). We use mediation analysis to evaluate whether peak inflammatory biomarkers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], D-dimer, ferritin, white blood cell count and interleukin-6) are in the causal pathway between obesity (BMI ≥ 30) and mechanical ventilation or death within 28 days of presentation to care.

RESULTS

In the MGH cohort (n = 1202), obesity was associated with greater likelihood of ventilation or death (OR = 1.73; 95% CI = [1.25, 2.41]; P = 0.001) and higher peak CRP (P < 0.001) compared with nonobese patients. The estimated proportion of the association between obesity and ventilation or death mediated by CRP was 0.49 (P < 0.001). Evidence of mediation was more pronounced in patients < 65 years (proportion mediated = 0.52 [P < 0.001] vs 0.44 [P = 0.180]). Findings were more moderate but consistent for peak ESR. Mediation by other inflammatory markers was not supported. Results were replicated in CUIMC/NYP cohort (n = 2626).

CONCLUSION

Findings support systemic inflammatory pathways in obesity-associated severe COVID-19 disease, particularly in patients < 65 years, captured by CRP and ESR. Contextualized in clinical trial findings, these results reveal therapeutic opportunity to target systemic inflammatory pathways and monitor interventions in high-risk subgroups and particularly obese patients.

摘要

背景

肥胖是 COVID-19 重症的既定危险因素。但肥胖与这种关联的机制基础尚不清楚。

目的

评估全身炎症在肥胖与 COVID-19 结局相关中的介导作用。

方法

这项基于医院的观察性研究纳入了 2020 年 2 月至 5 月在马萨诸塞州综合医院(MGH)或哥伦比亚大学欧文医学中心/纽约长老会医院(CUIMC/NYP)住院的 3828 例 SARS-CoV-2 感染患者。我们使用中介分析来评估峰值炎症生物标志物(C 反应蛋白[CRP]、红细胞沉降率[ESR]、D-二聚体、铁蛋白、白细胞计数和白细胞介素-6)是否存在于肥胖(BMI≥30)与就诊后 28 天内机械通气或死亡之间的因果途径中。

结果

在 MGH 队列(n=1202)中,肥胖与通气或死亡的可能性更大(比值比[OR]=1.73;95%置信区间[CI]=[1.25,2.41];P=0.001),并且与非肥胖患者相比,CRP 峰值更高(P<0.001)。肥胖与通气或死亡之间的关联被 CRP 介导的比例估计为 0.49(P<0.001)。在年龄<65 岁的患者中,这种中介作用更为明显(被介导的比例为 0.52[P<0.001] vs. 0.44[P=0.180])。其他炎症标志物的中介作用则不明显。在 CUIMC/NYP 队列(n=2626)中也得到了类似的结果。

结论

这些发现支持肥胖与 COVID-19 重症之间的全身性炎症途径,特别是在年龄<65 岁的患者中,这些途径可以用 CRP 和 ESR 来捕获。在临床试验结果的背景下,这些结果揭示了针对全身炎症途径的治疗机会,并在高危亚组,特别是肥胖患者中监测干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/8764215/1d63b71e6a9a/dgab629f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/8764215/bf898f9918ec/dgab629f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/8764215/1d63b71e6a9a/dgab629f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/8764215/bf898f9918ec/dgab629f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/8764215/1d63b71e6a9a/dgab629f0002.jpg

相似文献

1
Understanding the Link Between Obesity and Severe COVID-19 Outcomes: Causal Mediation by Systemic Inflammatory Response.理解肥胖与严重 COVID-19 结局之间的关联:系统性炎症反应的因果中介作用。
J Clin Endocrinol Metab. 2022 Jan 18;107(2):e698-e707. doi: 10.1210/clinem/dgab629.
2
The role of obesity in inflammatory markers in COVID-19 patients.肥胖在 COVID-19 患者炎症标志物中的作用。
Obes Res Clin Pract. 2021 Jan-Feb;15(1):96-99. doi: 10.1016/j.orcp.2020.12.004. Epub 2020 Dec 23.
3
The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis.与 COVID-19 相关的儿童(MIS-C)和青少年多系统炎症综合征的炎症标志物:一项荟萃分析。
J Med Virol. 2021 Jul;93(7):4358-4369. doi: 10.1002/jmv.26951. Epub 2021 Apr 1.
4
Identifying the Probable Etiology of Acute Undifferentiated Fever through Inflammatory Markers.通过炎症标志物识别急性未分化发热的可能病因。
J Assoc Physicians India. 2024 May;72(5):13-16. doi: 10.59556/japi.72.0523.
5
The inflammatory biomarkers profile of hospitalized patients with COVID-19 and its association with patient's outcome: A single centered study.COVID-19 住院患者的炎症生物标志物特征及其与患者预后的关系:一项单中心研究。
PLoS One. 2021 Dec 2;16(12):e0260537. doi: 10.1371/journal.pone.0260537. eCollection 2021.
6
Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection : A Retrospective Cohort Study.体重指数与 SARS-CoV-2 感染患者气管插管或死亡风险:一项回顾性队列研究。
Ann Intern Med. 2020 Nov 17;173(10):782-790. doi: 10.7326/M20-3214. Epub 2020 Jul 29.
7
Study of Association of Infection-related Biomarkers and Inflammatory Cytokines with the Severity of Coronavirus Disease 2019: A Prospective Observational Study.新型冠状病毒病 2019 严重程度相关感染生物标志物和炎症细胞因子的关联研究:一项前瞻性观察研究。
J Assoc Physicians India. 2024 Aug;72(8):44-47. doi: 10.59556/japi.72.0616.
8
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.《纽约市 COVID-19 重症成人的流行病学、临床病程和结局:一项前瞻性队列研究》
Lancet. 2020 Jun 6;395(10239):1763-1770. doi: 10.1016/S0140-6736(20)31189-2. Epub 2020 May 19.
9
Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.基本预测 COVID-19 患者细胞因子风暴的风险因素。
Front Immunol. 2021 Nov 10;12:745515. doi: 10.3389/fimmu.2021.745515. eCollection 2021.
10
Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients.COVID-19 感染患者血液学和免疫学标志物的诊断和预后价值:6320 例患者的荟萃分析。
PLoS One. 2020 Aug 21;15(8):e0238160. doi: 10.1371/journal.pone.0238160. eCollection 2020.

引用本文的文献

1
Sex-specific Mendelian randomization phenome-wide association study of basal metabolic rate.基础代谢率的性别特异性孟德尔随机化全表型关联研究
Sci Rep. 2025 Apr 24;15(1):14368. doi: 10.1038/s41598-025-98017-9.
2
Sex differences in the relationship between body composition and cardiac structure and function.身体成分与心脏结构和功能之间关系的性别差异。
Eur Heart J Cardiovasc Imaging. 2025 Jan 31;26(2):337-348. doi: 10.1093/ehjci/jeae264.
3
Long-Term Interplay Between SARS-CoV-2 and Renal Impairment.新型冠状病毒2019(SARS-CoV-2)与肾功能损害的长期相互作用

本文引用的文献

1
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.COVID-19 住院患者中使用他汀类药物前史与死亡率降低的关联。
Nat Commun. 2021 Feb 26;12(1):1325. doi: 10.1038/s41467-021-21553-1.
2
Massachusetts general hospital Covid-19 registry reveals two distinct populations of hospitalized patients by race and ethnicity.麻萨诸塞综合医院的 COVID-19 注册研究揭示了按种族和民族划分的两类住院患者。
PLoS One. 2020 Dec 22;15(12):e0244270. doi: 10.1371/journal.pone.0244270. eCollection 2020.
3
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
Cureus. 2024 Aug 10;16(8):e66553. doi: 10.7759/cureus.66553. eCollection 2024 Aug.
4
Changes in Circulating Adipokine Levels in COVID-19 Patients.新冠病毒肺炎患者循环中脂肪因子水平的变化
J Clin Med. 2024 Aug 14;13(16):4784. doi: 10.3390/jcm13164784.
5
CRP Monitoring in Early Hospitalization: Implications for Predicting Outcomes in Patients with COVID-19.住院早期的CRP监测:对预测COVID-19患者预后的意义
Pathogens. 2023 Nov 4;12(11):1315. doi: 10.3390/pathogens12111315.
6
Circulating neutrophil extracellular trap (NET)-forming 'rogue' neutrophil subset, immunotype [DEspR + CD11b +], mediate multi-organ failure in COVID-19-.循环中的中性粒细胞胞外诱捕网(NET)形成的“流氓”中性粒细胞亚群,免疫表型为[DEspR + CD11b +],介导新冠病毒疾病中的多器官功能衰竭。
Transl Med Commun. 2023;8(1):12. doi: 10.1186/s41231-023-00143-x. Epub 2023 Apr 18.
7
Associations of body mass index with severe outcomes of COVID-19 among critically ill elderly patients: A prospective study.危重症老年患者中体重指数与新型冠状病毒肺炎严重结局的关联:一项前瞻性研究。
Front Nutr. 2023 Feb 22;10:993292. doi: 10.3389/fnut.2023.993292. eCollection 2023.
8
Obesity-Associated Hepatic Steatosis, Somatotropic Axis Impairment, and Ferritin Levels Are Strong Predictors of COVID-19 Severity.肥胖相关性肝脂肪变性、躯体发育轴损害和铁蛋白水平是 COVID-19 严重程度的强有力预测指标。
Viruses. 2023 Feb 9;15(2):488. doi: 10.3390/v15020488.
9
Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity.全蛋白质组孟德尔随机化研究提示,肾病蛋白聚糖作为肥胖对 COVID-19 严重程度影响的可操作介质。
Nat Metab. 2023 Feb;5(2):248-264. doi: 10.1038/s42255-023-00742-w. Epub 2023 Feb 20.
10
Circulating neutrophil extracellular trap (NET)-forming 'rogue' neutrophil subset, immunotype [DEspR+CD11b+], mediate multi-organ failure in COVID-19 - an observational study.循环中形成中性粒细胞胞外陷阱(NET)的“ rogue”中性粒细胞亚群,免疫表型为[DEspR + CD11b +],介导COVID-19中的多器官功能衰竭——一项观察性研究。
Res Sq. 2023 Feb 1:rs.3.rs-2479844. doi: 10.21203/rs.3.rs-2479844/v1.
托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
4
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
5
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响:REMAP-CAP COVID-19 皮质类固醇随机临床试验。
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
6
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联:一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
7
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection.新型冠状病毒感染患者循环髓系细胞和浆细胞样树突状细胞的数量和质量变化。
Immunology. 2020 Dec;161(4):345-353. doi: 10.1111/imm.13254. Epub 2020 Oct 6.
8
Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity.肥胖的 COVID-19 患者死亡率较高,可能与高凝状态和脂肪组织炎症加重有关。
Front Endocrinol (Lausanne). 2020 Jul 28;11:530. doi: 10.3389/fendo.2020.00530. eCollection 2020.
9
Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19.糖尿病作为新冠病毒病住院患者早期预后不良的一个风险因素
Diabetes Care. 2020 Dec;43(12):2938-2944. doi: 10.2337/dc20-1506. Epub 2020 Aug 26.
10
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.血清钙卫蛋白和异常髓系细胞亚群可区分 COVID-19 重症与轻症。
Cell. 2020 Sep 17;182(6):1401-1418.e18. doi: 10.1016/j.cell.2020.08.002. Epub 2020 Aug 5.